Literature DB >> 10208663

Percutaneous embolization to control intractable epistaxis in nasopharyngeal carcinoma.

J S Mok1, J N Marshall, M Chan, C A van Hasselt.   

Abstract

BACKGROUND: Epistaxis in patients with nasopharyngeal carcinoma (NPC) who have received radiotherapy can be difficult to control by conventional methods. The use of angiography and embolization to control problematic epistaxis has been well documented in other situations, but its use in severe or recurrent epistaxis following irradiation for NPC has not been described.
METHODS: We retrospectively reviewed case notes of all patients with NPC initially seen with epistaxis over a 4-year period. Those patients with refractory epistaxis which could not be controlled by conventional methods and required angiography and embolization were assessed.
RESULTS: Eight patients who underwent angiography were identified. Five patients showed hypervascularization and three patients had pseudoaneurysms or an aneurysm of the internal carotid artery seen on the angiogram. All these patients were successfully embolized. There were no significant complications after the procedure.
CONCLUSION: We conclude that embolization is a safe and effective method of controlling refractory epistaxis in patients irradiated for NPC.

Entities:  

Mesh:

Year:  1999        PMID: 10208663     DOI: 10.1002/(sici)1097-0347(199905)21:3<211::aid-hed5>3.0.co;2-c

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  9 in total

1.  Radiation acute carotid blowout syndromes of the ascending pharyngeal and internal carotid arteries in nasopharyngeal carcinoma.

Authors:  Chao-Bao Luo; Michael Mu-Huo Teng; Feng-Chi Chang
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-03-15       Impact factor: 2.503

Review 2.  Transcatheter embolization in the management of epistaxis.

Authors:  Gregory J Dubel; Sun Ho Ahn; Gregory M Soares
Journal:  Semin Intervent Radiol       Date:  2013-09       Impact factor: 1.513

3.  Transcutaneous arterial embolization to control massive tumor bleeding in head and neck cancer: 63 patients' experiences from a single medical center.

Authors:  Wen-Chi Chou; Chang-Hsien Lu; Gigin Lin; Yu-Shin Hong; Ping-Tsung Chen; Hung-Chih Hsu; Jen-Shi Chen; Kun-Yun Yeh; Hung-Ming Wang; Chuang-Chi Liaw
Journal:  Support Care Cancer       Date:  2007-03-14       Impact factor: 3.603

4.  The role of computed tomography angiography as initial imaging tool for acute hemorrhage in the head and neck.

Authors:  M Travis Caton; Nityanand Miskin; Jeffrey P Guenette
Journal:  Emerg Radiol       Date:  2020-08-05

5.  Repeated massive epistaxis after re-irradiation in recurrent nasopharyngeal carcinoma.

Authors:  Hai-Yan Chen; Xiu-Mei Ma; Yong-Rui Bai
Journal:  Contemp Oncol (Pozn)       Date:  2014

6.  Etiology and management of nasopharyngeal hemorrhage after radiotherapy for nasopharyngeal carcinoma.

Authors:  Jiabin Zhan; Shuai Zhang; Xin Wei; Yihui Fu; Jing Zheng
Journal:  Cancer Manag Res       Date:  2019-03-15       Impact factor: 3.989

7.  Endovascular Management of Intractable Nasopharyngeal Hemorrhage in Patients Irradiated for Nasopharyngeal Carcinoma: A Twelve-Year Experience.

Authors:  Yingliang Wang; Xiangjun Dong; Chen Zhou; Qin Shi; Jiacheng Liu; Bin Xiong
Journal:  Cancer Manag Res       Date:  2020-11-20       Impact factor: 3.989

8.  Ruptured internal carotid artery aneurysm presenting with catastrophic epistaxis after repeated stereotactic radiotherapies for anterior skull base tumor: case reports and review of the literature.

Authors:  Koji Fujita; Manabu Tamura; Osamu Masuo; Takahiro Sasaki; Toshikazu Yamoto; Junya Fukai; Naoyuki Nakao
Journal:  J Neurol Surg Rep       Date:  2014-08-05

9.  Long-term survival and late complications of intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma.

Authors:  Fangfang Kong; Junjun Zhou; Chengrun Du; Xiayun He; Lin Kong; Chaosu Hu; Hongmei Ying
Journal:  BMC Cancer       Date:  2018-11-20       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.